East Ocyon Bio develops advanced cell and gene therapies focused on oncology. The company specializes in engineering Chimeric Antigen Receptor Natural Killer (CAR-NK) cells for cancer treatment applications. This platform aims to provide novel immunotherapeutic options for patients with various malignancies.
Funding
$4.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MLFounders
Product
Problem
Many cancers, especially solid tumors, are difficult to treat effectively with existing therapies. Traditional approaches may not fully eradicate cancer cells or prevent recurrence, and can have significant side effects. There is a need for more targeted and effective treatments that can improve patient outcomes and reduce the burden of cancer.
Solution
East Ocyon Bio develops allogeneic cell therapies using natural killer (NK) cells and Gamma Delta T cells engineered with synthetic biology and non-viral cell engineering to enhance their tumor-targeting capabilities. Their off-the-shelf CAR-NK cell therapies are designed to treat challenging cancers, including solid tumors and hematological malignancies, by combining new functional attributes with the inherent cancer-fighting properties of NK cells. The company's integrated platform combines advanced cell engineering and viral vector technologies to develop novel immunotherapies with superior efficacy and safety profiles. East Ocyon Bio's approach aims to provide more effective treatment options for cancer patients, with a focus on early and affordable access to these therapies.
Target Audience
East Ocyon Bio's primary target audience includes patients with solid tumors, hematological malignancies, and autoimmune diseases, as well as clinicians and researchers seeking advanced cell-based immunotherapies.
Features
- Genetically engineered NK cell therapies targeting PDL1 and EGFR for solid tumors and NHL
- Genetically engineered gamma delta T-cell therapy targeting CD19 for hematologic cancers
- Non-engineered NK cell therapy for GBM (Glioblastoma Multiforme)
- Proprietary platform for NK cell engineering and expansion
- Gamma Retroviral vector production for gene delivery
- Capability to isolate and activate Gamma Delta T cells
- GMP-grade viral vector production services using transient transfection and stable packaging cell-line-based processes
- Molecular biology and analytical laboratories, along with quality control and testing facilities